Global Healthcare Investing Conference: Advisory Board

Home

Advisory Board

Baiju R. Shah
Anthony G. Viscogliosi
Dean Banks
Steve Burrill
Norman Chen

Kent Gossett
Avshalom Horan
Andrew Jay
Daniel Kosoy
Carol Kovac
Frank Kung

Vivian Lee
Ting Pau Oei
Sanuj Ravindran
Sanjay Sehgal
Dr. Anthony Sun
Gerald Turner

Conference Co-Chairs

Baiju R. Shah: President
BioEnterprise Corporation; Baiju R. Shah is President and CEO of BioEnterprise, a partnership of Case Western, Cleveland Clinic, Summa Health, and University Hospitals. BioEnterprise is a business acceleration initiative to support the growth of bioscience companies. Since 2002, it has helped more than 60 Cleveland companies that have collectively attracted more than $600 million in new funding. Prior to BioEnterprise, Shah was with McKinsey & Company, where he played a leading role in the Growth and Business Building practice. In the community, Shah serves on Boards of The Saint Luke’s Foundation, Great Lakes Science Center, Yale Alumni Association, NorTech, and Summer on the Cuyahoga, and also the Governor’s Workforce Policy Board and Strategic Development Advisory Board. Shah received a J.D. from Harvard and his B.A. from Yale.

Anthony G. Viscogliosi: Principal
Viscogliosi Bros., LLC; Mr. Viscogliosi founded Small Bone Innovations, Inc. (SBI) in 2004 and raised $42.2 million in 2005 – then the largest ever round of VC financing in orthopedics. SBI was recognized by Red Herring – in 2006 – as a Top 100 Technology Company in North America and – in 2007 – a Top 100 Global startup company – the only orthopedics company chosen. SBI was also honored by consulting firm, Frost & Sullivan, as 2007’s Entrepreneurial Company of the Year. In 1999, he co-founded Viscogliosi Bros. LLC a banking firm that has helped 170 companies, including SBi. Mr. Viscogliosi received an Honorary Degree of Doctor of Humane Letters-Honors Causa (D.H.L) from the NY College of Podiatric Medicine, in 2007, and his B.S. in Economics from the University of Michigan in 1984.

Members

Dean Banks: Vice President
Highland Capital Partners; Dean Banks is a Vice President at Highland Capital Partners focusing on healthcare investments and specializing in medical devices and diagnostics. Prior to joining Highland, Dean was an Associate Principal at Cytyc Corporation, a leading diagnostic and medical device company dedicated to the improvement of women's health. Before joining Cytyc, Dean worked for Cambridge Endoscopic Devices as a VP of Business Development and Marketing. Dean began his business career at Ethicon Endo-Surgery, a J&J company marketing advanced medical devices for minimally invasive surgical procedures. During his five-year tenure, he held a variety of positions in management, sales and professional education. Dean received his B.A from Miami University and his M.B.A from Harvard Business School.

Steve Burrill: Partner
Burrill & Company; G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Pharmasset (NASDAQ: VRUS) and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, hytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).

Norman Chen: Partner, Healthcare
Fidelity Asia Ventures Ltd; Norman Chen joined Fidelity Asia Ventures in 2005 and has over 15 years of experience as a senior executive, entrepreneur and venture capitalist in the healthcare industry in Asia. He began his healthcare career at Baxter International, where he was responsible for sales and marketing of medical equipment and supplies across 13 markets in Asia from 1991-1995. In 1996, Norman founded Asia Renal Care (ARC), a leading provider of kidney dialysis services in Asia. Investors included Fidelity Asia Ventures, Investor AB, Walden International, and Satellite Dialysis Centers, a strategic partner based in the SF Bay area affiliated with Stanford University. As CEO and Vice-Chairman, Norman led the company’s growth over 10 years to over 70 dialysis centers in Taiwan, Singapore, Philippines, Japan, Korea and Malaysia. From 2002-2003, Norman was an Entrepreneur-in-Residence at Walden International. He has a Bachelor’s Degree in Biology from MIT and an MBA from Stanford University.

Kent Gossett: Principal
SR One; Kent joined SR One in 2003 after three years at GSK Ventures. He is a member of the Board of Directors of Algeta ASA, Protez Pharmaceuticals, CalciMedica, and Resistentia Pharmaceuticals AB. He was previously Director of Alere Medical and Observer for TorreyPines Therapeutics and Morphotek Inc. Kent has held positions in Scientific Licensing (1999-2000) Clinical Pathology and Safety Pharmacology (1993-1999) at SmithKline Beecham Pharmaceuticals, Assistant Research Director of Clinical Pathology at Sterling Winthrop Pharmaceuticals (1989-1992) and Assistant/ Associate Professor of Veterinary Clinical Pathology at Louisiana State University. Kent received his DVM and MS from Purdue University, his PhD in Veterinary Clinical Pathology from Louisiana State University, is a Diplomat of the American College of Veterinary Pathologists, and received his MBA from the Wharton School of the University of Pennsylvania.

Avshalom Horan: Managing Partner
Bridge Investment Fund L.P.; Dr. Avshalom Horan is a Managing Partner at the Bridge Investment Fund – a VC based in Cleveland and Tel Aviv, focused on investing in Israeli early stage med-tech companies that are getting ready to launch their US operation. Horan has an extensive background in seed investment and management of technology companies through their early stages. During his service in the Israeli Military Intelligence, he headed a special department overseeing the development of major projects involving state of the art technologies. Horan was the VP of a technology subsidiary of the Bank Leumi Investment Group and has served on the board of directors of several private and public Israeli companies. He founded and directed a technology incubator in Israel where several startup companies were seed funded. Horan is the chairman of Simbionix, a company that was started in that incubator and has later co-located in Cleveland. Simbionix is a lead developer of surgical simulation systems with over $10 million in revenue in 2007. Horan is a venture partner with Tenne, an Israeli Private Equity Fund. He holds a Ph.D. in Engineering-Economic Systems from Stanford University, and is a decorated Colonel (res.) in the Israeli Defense Forces (IDF).

Andrew Jay: Managing Partner, Medical Solutions Fund
Siemens Venture Capital, Inc.; Dr. Andrew Jay is Head of the Medical Fund at Siemens Venture Capital. He currently is on the Board of Directors of Molecular Insight Pharmaceuticals, RadPharm, U-Systems, and Vasomed. He is also involved with MDdatacor, Sequenom and Cylex. Dr. Jay previously was a medical technology analyst at Wachovia Securities and Deutsche Bank. He was instrumental in raising over $2 billion in equity capital, publishing over 10,000 pages of research and bringing 30 medical technology companies public. He was frequently interviewed in the financial trade press including the Wall Street Journal, CNN and MSNBC. He has a Bachelor of Science from Rensselaer Polytechnic Institute, a DMD from the University of Pennsylvania and an MBA from the Kellogg School at Northwestern.

Daniel Kosoy: Partner
Athenian Venture Partners; Daniel Kosoy MD is a transplant surgeon and the San Diego Partner of Athenian Venture Partners, an Ohio based national venture capital firm investing in IT and Life Science companies. He has worked in venture capital since 1999 investing in biotechnology, pharmaceuticals and medical devices. From 1988-1990 he was a management consultant at Scientific Generics, in Cambridge, England, consulting to pharmaceutical, agrochemical, biotechnology and diagnostics companies. He has a BA from Yale University, an MD from McGill University, and is a Fellow of the American College of Surgeons and a Fellow of the Royal College of Surgeons of Canada. He is a Director at Windy Hill Medical, and an observer at CancerVax, Verus Pharmaceuticals, Archemix, Akebia Therapeutics, and LigoCyte Pharmaceuticals.

Carol Kovac: Partner
Burrill & Company; Dr. Kovac joined Burrill & Company after retiring from IBM, where she was responsible for the strategic direction of IBM's global healthcare and life sciences business. She led a team in developing the latest information technology solutions and services, establishing partnerships and overseeing IBM investment within the healthcare, pharmaceutical and life sciences markets. In more than 20 years at IBM, Dr. Kovac held a number of executive management positions, including vice president at IBM Research, where she was instrumental in launching the Computational Biology Center and the massive Blue Gene supercomputer project. Starting with only two employees as an emerging business unit in the year 2000, Dr. Kovac successfully grew IBM's life sciences business unit into a multi-billion dollar business, and one of IBM's most successful ventures to date with more than 1500 employees worldwide. Her main focus at Burrill is developing and executing investment strategies for leading edge technologies that are contributing to the transformation of medicine and healthcare including: personalized medicine, the use of IT in healthcare, stem cell research, medical devices and diagnostics, and bio-nanotechnology. In addition, she will work as part of the Burrill International Group team building the company's life science focus on emerging economies such as China, India, Malaysia and the Middle East.

Frank Kung: Managing Partner
Vivo Ventures; Frank Kung is a founder and managing member of the Palo Alto, CA based Vivo Ventures, LLC, a venture capital management firm established in 1996, currently with more than $650MM under management. He joined Cetus Corporation in 1979, co-founded Cetus Immune Corporation in 1981. In 1984 he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. He brought the company public in 1991, and built it to a 175 employee international biotech company. Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and MBA from the University of California, Berkeley. He currently serves on the board of directors of a number of biotechnology companies.

Vivian Lee: Managing Director
Aqua Partners LLC; With Aqua Partners, a strategic and financial advisory firm she founded in 1983, Vivian has worked with numerous companies, investment firms, universities and government agencies worldwide. She served as a reviewer to the US Congressional Office of Technology Assessment in its first report on commercial biotechnology, and her analyses of biotechnology industry and financing trends have been published by Bio/Technology, BioIndustry (Japan), In Vivo, Biotechnology News, Decision Resources and Drug & Market Development. As a venture partner managing International Biomedicine Fund, she served as a director on the board of Innodia, and as an observer on the board of Syntonix Pharmaceuticals. Vivian began her career as a venture analyst at WR Grace & Co.

Ting Pau Oei: Partner
L Capital; Ting Pau Oei is a Partner of L Capital Partners SBIC, LLP and leads the firm’s efforts in healthcare investments. Mr. Oei joined L Capital Partners in 2004 after a distinguished 22 year career at Johnson & Johnson. Mr. Oei has been in the venture capital business for over 15 years, invested in over 55 venture backed private healthcare companies. Mr. Oei has made investments in a broad range of companies including early-stage startups to developmental/growth stage companies to investments in public companies. Currently, Mr. Oei is on the board of directors of Protez Pharmaceuticals, Inc., CeNeRx BioPharma, Inc., IntraPace Inc., ProRhythm, Inc. and Locus Pharmaceuticals, Inc. Mr. Oei received his undergraduate degree from Union College (N.Y.) and MBA from Columbia Business School.

Sanuj K. Ravindran: Principal
Radius Ventures; Sanuj K. Ravindran, M.D. is a Principal of Radius Ventures. Prior to joining Radius in February 2007, Sanuj was a Director at Burrill & Company, a San Francisco based life science venture capital firm. While with Burrill, he served as a board observer to diaDexus and Proventys, and played an active role in several other investments, including Endocyte, Neosil, Cardiokine and Arete Therapeutics. Previously, Sanuj worked in the Healthcare Investment Banking Group at Merrill Lynch. He is Board Certified in Internal Medicine and served as a National Cancer Institute Research Fellow at Memorial Sloan Kettering Cancer Center. He is also a member of the Kauffman Fellows Program. Sanuj received a B.A. with Honors from Northwestern University, an M.D. from Jefferson Medical College, and an M.B.A from The Kellogg School of Management, where he was a Rothschild Scholar.

Sanjay Sehgal: Managing Partner & CEO
East West Capital Partners Pty. Ltd.; Sanjay Sehgal is a founder and Managing Partner & CEO of East West Capital Partners, a healthcare-focused private equity firm based out of Singapore and Bangalore. Prior to EWCP, Sanjay was a Partner and member of the investment committee at Symphony Capital Partners (Asia) (f.k.a Schroder Capital Partners) focused doing development capital and buy-outs throughout the Asia-Pacific region. Prior to joining SCP in 1994, Sanjay was a Manager in the Boston office of LEK Consulting, an international strategy consulting firm. Sanjay has a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology, an MSc. in Electrical Engineering from Columbia University, New York and an MBA, with distinction, in finance and multinational management from The Wharton School of the University of Pennsylvania.

Dr. Anthony Sun: Principal
Aisling Capital; Dr. Sun joined Fund I in 2001-2002 and currently serves as a Principal. Previously, Dr. Sun was an entrepreneur co-founding a disease management company and an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania. Dr. Sun currently serves as a director of CeNeRx BioPharma, Inc., Dynova Laboratories, Inc., HerbalScience, Inc., and Paratek Pharmaceuticals, Inc. Previously, he served on the board of MAP Pharmaceuticals, Inc. ("MAPP": NASDAQ). Dr. Sun received his B.S. in Electrical Engineering from Cornell University and his M.D. from Temple University School of Medicine with A.O.A. honors. In addition, he is a Board Certified Internist and has an M.B.A. from The Wharton School at the University of Pennsylvania.

Gerald Turner: General Partner
Seraphim Capital \ Focus Enterprises; Gerald Turner is a Managing Director at Focus LLC, a leading middle market investment bank, headquartered in Washington, D.C. with offices in Atlanta, Chicago and San Francisco. Mr. Turner’s practice is trans-Atlantic in scope. He is also a founder and Investment Director of Seraphim Capital, a London, England, based early stage venture capital fund. He is a founder of Atlantic BioBridge, a consultancy designed to deliver services to build global life science businesses on both sides of the Atlantic. He represents FOCUS on the Board of Advisors of the Business Growth Alliance, a group of service providers to family owned businesses. He is a Member of the British-North American Committee, a forum for business and academic leaders from the United States, Canada and Britain. Mr. Turner was educated at Oxford University, at the Wharton Graduate School of Business, and at the Harvard Graduate School of Business.